Login to Your Account



Other News To Note


Wednesday, February 6, 2013
• AiCuris GmbH, of Wuppertal, Germany, said it achieved more than 50 percent patient enrollment in the second efficacy trial of herpes simplex virus (HSV) drug pritelivir (formerly AIC316). The study is comparing the potency of pritelivir to valacyclovir in reducing genital HSV shedding.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription